Hopp til hovedinnhold

Ulcerøs kolitt

Sist revidert:
Sist revidert av:


Definisjon:
Uspesifikk, sammenhengende slimhinneinflammasjon i kolon. Årsaken er ukjent, økt forekomst hos førstegradsslektninger av personer med tilstanden.
Forekomst:
Insidensen er økende, ca 14 per 100.000 per år i Norge.
Symptomer:
Blodig og slimet diaré.
Funn:
Varierer med sykdomsaktivitet og utbredelse. Ømhet ved palpasjon av abdomen. Blekhet ved anemi.
Diagnostikk:
Hb, SR, CRP, hvite, trombocytter og albumin gir en indikasjon på systemisk påvirkning. Kalprotektin i avføring som screening og ved mistenkt forverring. Koloskopi.
Behandling:
5-ASA, ev. kortikosteroider benyttes initialt. Immunmodulerende behandling og biologiske legemidler ved mangelfull effekt og ved tilbakefall. Manglende respons på behandling er indikasjon for kolektomi.
  1. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis, Volume 13, Issue 2, February 2019, Pages 144–164K . academic.oup.com  
  2. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753. PubMed  
  3. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010;16:112-124. PubMed  
  4. Ghouri YA, Tahan V, Shen B. Secondary causes of inflammatory bowel diseases. World J Gastroenterol. 2020;26(28):3998-4017. PubMed  
  5. Bastida G, Beltran B. Ulcerative colitis in smokers, non-smokers and ex-smokers. World J Gastroenterol. 2011 Jun 14; 17(22): 2740–2747. www.ncbi.nlm.nih.gov  
  6. Moum B. Ulcerøs kolitt, Crohns sykdom og 5-aminosalisylsyreforbindelser. Tidsskr Nor Lægeforen 2003; 123: 2565-7. PubMed  
  7. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12: 4819-31. PubMed  
  8. Grimstad T, Norheim KB. Fatigue in inflammatory bowel disease. Utmattelse ved inflammatorisk tarmsykdom. Tidsskr Nor Laegeforen. 2016;136(20):1721-1724. Published 2016 Nov 8. PMID: 27830906 PubMed  
  9. Gomollón F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol. 2009;15(37):4659-4665. PubMed  
  10. Jahnsen J, Røseth AG, Aadland E. Måling av kalprotektin i feces. Tidsskr Nor Legeforen 2009; 129: 743-5. Tidsskrift for Den norske legeforening  
  11. van Rheenen PF, De Vijver EV, Fidler F. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369. BMJ (DOI)  
  12. Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol 2014; 12: 253-62. pmid:23883663 PubMed  
  13. Turvill J. High negative predictive value of a normal faecal calprotectin in patients with symptomatic intestinal disease. Frontline Gastroenterology 2012; 3: 21-8. PubMed  
  14. Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. Am J Gastroenterol. 2015. doi: 10.1038/ajg.2015.120 DOI  
  15. Cima RR, Pemberton JH. Medical and surgical management of chronic ulcerative colitis. Arch Surg 2005; 140: 300-10. PubMed  
  16. Lange P. Biologisk behandling af colitis ulcerosa. Ugeskriftet, 25.10.2019. ugeskriftet.dk  
  17. Feagan LG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; (2): CD000544. Cochrane (DOI)  
  18. Hauso Ø, Martinsen TC, Waldum H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scand J Gastroenterol 2015;50:933-41. pmid:25733192 PubMed  
  19. Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 21-9. PubMed  
  20. Nielsen OH, Gubatan JM, Juhl CB, et al. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)31281-7. PMID: 32931960 PubMed  
  21. Zhan YL, Zhan YA, Dai SX. Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis and systematic review. Clin Nutr. 2017 May 24 . pmid:28587774 PubMed  
  22. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16(1):2-17. PubMed  
  23. Martinsen TC, Herter R, Dybdahl JH, Waldum L. Bruk av TNF-α-Antistoff ved inflammatorisk tarmsykdom. Tidsskr Nor Legeforen 2010; 130: 273-7. Tidsskrift for Den norske legeforening  
  24. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014 ;39(7):660-71. doi: 10.1111/apt.12644.
  25. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146:392. doi.org/10.1053/j.gastro.2013.10.052
  26. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266-275. PubMed  
  27. Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372-2384. PubMed  
  28. Sands BE, Peyrin-Biroulet L, Loftus EV et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 2019;381:1215-26. New England Journal of Medicine  
  29. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019;114:384-413. PubMed  
  30. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Eng J Med 2005; 353: 2462-76. PubMed  
  31. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013 May 7. pmid:23649185 PubMed  
  32. LeBlanc K, Mosli MH, Parker CE, MacDonald JK. The impact of biological interventions for ulcerative colitis on health‐related quality of life. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD008655. DOI: 10.1002/14651858.CD008655.pub3. DOI  
  33. Timmer A, Patton PH, Chande N, et al. Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD000478. DOI: 10.1002/14651858.CD000478.pub4. DOI  
  34. Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014 ;8:CD006618. DOI: 10.1002/14651858.CD006618.pub3 DOI  
  35. Herfarth H, Barnes EL, Valentine JF, et al. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology 2018. pmid:29964043 PubMed  
  36. Wang Y, MacDonald JK, Benchimol EI, et al. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD006790. DOI: 10.1002/14651858.CD006790.pub3. DOI  
  37. Wang Y, MacDonald JK, Vandermeer B, Griffiths AM, El-Matary W. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2015, Issue 8. Art. No.: CD007560. DOI: 10.1002/14651858.CD007560.pub3. DOI  
  38. Kikut J, Konecka N, Ziętek M, Kulpa D, Szczuko M. Diet supporting therapy for inflammatory bowel diseases. Eur J Nutr. 2021;60(5):2275-2291. PubMed  
  39. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015; 149: 102-9. DOI:10.1053/j.gastro.2015.04.001 DOI  
  40. Haifer C, Paramsothy S, Kaakoush NO, et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2021. pmid:34863330 PubMed  
  41. Solberg C, Lygren I Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44(4): 431-40. DOI: 10.1080/00365520802600961.
  42. Johnson E, Hoel TN, Nazir M, Carlsen E. Kirurgisk behandling ved ulcerøs kolitt. Tidsskr Nor Lægeforen 1999; 19: 3124-6. PubMed  
  43. Bülow S. Ileoanal pouch-kirurgi. Ugeskr Læger 2008; 170: 1719. PubMed  
  44. Bach SP, Mortensen NJM. Revolution and evolution: 30 years of ileoanal pouch surgery. Inflamm Bowel Dis 2006; 12: 131-45. PubMed  
  45. Allgayer H, Kruis W. Aminosalicylates: potential antineoplastic actions in colon cancer prevention. Scand J Gastroenterol 2002; 38: 125 - 31. PubMed  
  46. Torres J, Boyapati RK, Kennedy NA, et al. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology. 2015 ;149:1716-30. doi: 10.1053/j.gastro.2015.08.055. PMID:26381892 PubMed  
  47. Moum B, Ekbom A, Vatn M, Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 1999; 94: 1564-9. PubMed  
  48. Langholz E, Munkholm P, Davidsen M. Inflammatory bowel disease with onset in childhood: clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 1997; 32: 139-47. PubMed  
  49. Solberg C, Lygren I Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44(4): 431-40. DOI: 10.1080/00365520802600961. DOI  
  50. Henriksen M, Moum B. Kolorektal kreft ved inflammatorisk tarmsykdom. Tidsskr Nor Lægeforen 2007; 127: 2696-9. Tidsskrift for Den norske legeforening  
  51. Hovde Ø, Høivik ML, Henriksen M, et al. Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study. Journal of Crohn's and Colitis, 2017; 11 (5): 571–577. academic.oup.com  
  52. Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet 2020. doi:10.1016/S0140-6736(19)32545-0 DOI  
  53. Hovde Ø, Småstuen MC, Høivik ML, et al. Mortality and causes of death in ulcerative colitis: Results from 20 years of follow-up in the IBSEN study. Inflamm Bowel Dis 2016; 22(1):141-145. PubMed  
  54. Grimstad T, Norheim KB. Utmattelse ved inflammatorisk tarmsykdom. Tidsskr Nor Lægeforen 2016; 136: 1721-24. pmid:27830906 PubMed  
  55. Grimstad T, Norheim KB, Isaksen K. Fatigue in Newly Diagnosed Inflammatory Bowel Disease. J Crohns Colitis 2015; 9: 725-30. pmid:25994356 PubMed  
  56. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44(4): 431-40. PubMed  
  57. Moum B. Prognose og behandling ved kronisk inflammatorisk tarmsykdom. Tidsskr Nor Lægeforen 2001; 121: 318-21. Tidsskrift for Den norske legeforening  
  58. Katz J. The course of inflammatory bowel disease. Med Clin North Am 1994; 78: 1275-80. PubMed  
  59. Delco F, Sonnenberg A. A decision analysis of surveillance for colorectal cancer in ulcerative colitis. Gut 2000; 46: 500 - 6. Gut  
  60. Axon ATR. Cancer surveillance in ulcerative colitis - a time for reappraisal. Gut 1994; 35: 587 - 9. Gut  
  • Bjørn Moum, professor i gastroenterologi, Oslo Universitetssykehus

Tidligere fagmedarbeidere

  • Terje Johannessen, professor i allmennmedisin, Trondheim
  • Jan H. Dybdahl, overlege, dr.med., Medisinsk avdeling, St. Olavs Hospital, Trondheim